The ECM Pharmacology Conference (ECM2026) concludes today in Copenhagen, Denmark. It was great to see Lara Perryman, Senior Research Biologist at Syntara, present "Pan lysyl oxidase inhibitors: dual targeting of collagen cross linking and growth factor receptor oxidation in skin scars and myelofibrosis."   Lara's presentation explored the science behind Syntara's pan-LOX inhibitor programs, including amsulostat in myelofibrosis and myelodysplastic syndrome, and SNT-9465 in skin scarring.   📷 The conference also provided a valuable opportunity to catch up with collaborators and researchers from around the world, including Joan Chang and Professor Thomas Cox. $SNT #ECM2026 #Myelofibrosis #MDS #SkinScarring #DrugDevelopment #Biotech #Fibrosis

Dr Boreham’s Crucible: Syntara seeks its latest transformation | $SNT Media coverage by Tim Boreham and @Stockhead.   stockhead.com.au/experts/dr-…

“We’ve only got a $50 million market cap and a slate of phase II clinical trial readouts that normally trigger big jumps in value, $SNT CEO Gary Phillips. Syntara has been featured in the latest edition of Biotech Daily, highlighting our lead myelofibrosis program, ongoing studies in myelodysplastic syndrome, the Phase 2 iRBD study supported by Parkinson’s UK, and our skin scarring program. With five clinical study outcomes due this year and ongoing licensing discussions, 2026 continues to be a significant year for the Company. Read the full article here: biotechdaily.com.au/wp/wp-co… #Syntara #SNT #ASX #Biotech #ClinicalTrials #Myelofibrosis #ParkinsonsDisease #DrugDevelopment

Parkinson’s disease affects millions of people worldwide, with limited treatment options that meaningfully slow disease progression. In this video, Syntara outlines its latest clinical study targeting neuroinflammation in patients at risk of Parkinson’s and explains the science behind its approach. Watch until the end as Gary Phillips, CEO of Syntara talks about what is next for the company for the rest of 2026! #Syntara #ASXSNT #ParkinsonsDisease #Biotech #HealthcareInnovation

Syntara is targeting a significant unmet need in scar management, with the global scar treatment market estimated to be worth billions of dollars and growing rapidly as demand increases for effective treatments. In this KapitaList interview, CEO of Syntara, Gary Phillips discusses how Syntara is currently evaluating its topical pan-LOX inhibitor for scarring in a clinical trial and the commercial opportunity in treating pathological scarring. You can find Syntara on the ASX under the ticker SNT. #Syntara #ASX #SNT #Biotech #Biotechnology #HealthcareInnovation #StockMarket #KapitaList @NWRcomms

Introducing Syntara ASX: SNT. "A little bit different from the average biotech on the ASX." That's how Syntara CEO Gary Phillips describes the company. So what makes Syntara different, and why should investors be paying attention? We're here to tell you why. Watch the latest KapitaList interview with Gary Phillips as he discusses the company's unique approach, upcoming catalysts and what's next following the recent capital raise. #ASX #SNT #Biotech #Healthcare #Investing #KapitaList

SNT-4728 webinar presentation: June 2026 View the full $SNT Presentation here: cdn-api.markitdigital.com/ap…

We’re hosting an investor webinar at 12pm AEST on Monday 1 June 2026 to provide further information regarding our ongoing Phase 2 trial of SNT-4728, ahead of the topline data readout expected by the end of June. Syntara CEO Gary Phillips and Head of Drug Discovery Dr Wolfgang Jarolimek will be joined by Dr Lynsey Bilsland, Managing Director of Parkinson’s Research Venture, and Professor Simon Lewis, Neurologist & Trial Principal Investigator. Register here: us02web.zoom.us/webinar/regi… $SNT #Syntara #ASX #Biotech #ParkinsonsDisease #Neuroinflammation #ClinicalTrials #DrugDevelopment

Specialist healthcare investors back Syntara ahead of milestone rich period | Media coverage by @HotCopper. hotcopper.com.au/opinion/con… $SNT

Syntara CEO Gary Phillips spoke to ASX Briefs to break down the company's clinical pipeline, recent regulatory milestones, and its highly anticipated news flow for the remainder of the year. Listen to the full $SNT podcast here: open.spotify.com/episode/7JU… linkedin.com/safety/go/?url=…

Euroz Hartleys analyst Seth Lizee has maintained a Speculative Buy on @SyntaraTx (#ASX: $SNT) with a $0.16 price target, implying ~493% upside to the current share price of $0.027. The report follows positive FDA feedback supporting the Phase 2b design for amsulostat in myelofibrosis, with Euroz noting the outcome removes “the last major barrier” before advancing into the next stage of development. Euroz continues to view amsulostat as “a differentiated, potentially disease-modifying asset with significant commercial potential”, while highlighting five clinical readouts due across CY26, including Parkinson’s/iRBD, MDS and skin scarring programs. The note also points to growing strategic interest in the myelofibrosis space, referencing recent multi-billion dollar transactions involving Sanofi, Eli Lilly and Ajax Therapeutics.

We’re pleased to invite eligible shareholders to participate in Syntara’s Share Purchase Plan at the same issue price as the recent Placement, being A$0.027 per share. The Placement proceeds provide a cash runway to Q3 2027 and will support five key clinical trial readouts over CY2026, licensing discussions across the pipeline, preparation for the planned Phase 2b myelofibrosis study, and strengthening Syntara’s global leading pan-LOX patent suite. The SPP opens Thursday, 14 May 2026 and is expected to close Friday, 5 June 2026. Further $SNT details: cdn-api.markitdigital.com/ap… #Syntara #ASX #Biotech #ClinicalTrials #Myelofibrosis #DrugDevelopment

Syntara CEO Gary Phillips hosted an investor webinar to discuss recent updates, including the positive FDA feedback supporting the planned Phase 2b trial of amsulostat in myelofibrosis, as well as the capital raising undertaken by the Company. Watch the full $SNT replay here: youtu.be/_FYXK0FIgzY?si=uOEv… #Biotech #ASX

“Syntara (SNT: $0.029) has outcomes from five clinical studies due this year.” Syntara has been featured in the latest Bioshares "Syntara: First of Five Milestones Approaching", highlighting multiple approaching milestones across our pipeline, including the Phase 2 iRBD study with SNT-4728 and ongoing discussions with the FDA for amsulostat in myelofibrosis. Read the full $SNT report here: linkedin.com/feed/update/urn… #Syntara #SNT #ASX #Biotech #ClinicalTrials #Myelofibrosis #Parkinsons #DrugDevelopment

Webinar Presentation Positive FDA review of amsulostat Phase 2b trial plan View the full $SNT Presentation here: cdn-api.markitdigital.com/ap… #SNT #Syntara #Biotech #Webinar

We've released our Quarterly Activities Report for the period ending 31 March 2026. View the full $SNT report here: cdn-api.markitdigital.com/ap…

REMINDER | Syntara CEO Gary Phillips will host an investor webinar TODAY to discuss recent updates, including the positive FDA feedback supporting the planned Phase 2b trial of amsulostat in myelofibrosis, as well as the capital raising undertaken by the Company. 📅 11:00am AEST – Thursday 30 April 2026 Shareholders, investors and interested parties are encouraged to register here: us02web.zoom.us/webinar/regi… Questions can be submitted live during the webinar or sent in advance to matt@nwrcommunications.com.au A replay will be available shortly following the conclusion of the live session. $SNT

Syntara Receives Positive FDA Feedback for Myelofibrosis Drug Amsulostat | $SNT Media coverage by @sharecafetweets . sharecafe.com.au/2026/04/28/…

Health Check: Syntara goes to the well for $10 million to fund advanced cancer trial | $SNT Media coverage by @StockheadAU stockhead.com.au/health/heal…

Syntara CEO Gary Phillips will host an investor webinar to discuss recent updates, including the positive FDA feedback supporting the planned Phase 2b trial of amsulostat in myelofibrosis, as well as the capital raising undertaken by the Company. 📅 11:00am AEST – Thursday 30 April 2026 Shareholders, investors and interested parties are encouraged to register here: us02web.zoom.us/webinar/regi… Questions can be submitted live during the webinar or sent in advance to matt@nwrcommunications.com.au A replay will be available shortly following the conclusion of the live session. $SNT #Biotech